Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced today the completion of its acquisition of MacroGenics, Inc.'s (NASDAQ: MGNX) GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland and a warehousing center in Frederick, Maryland, for total consideration of US $122.5 million. The transaction, conducted through Bora's wholly owned subsidiary Bora Biologics USA, LLC, also includes a long-term CDMO Service Agreement with MacroGenics.
With this acquisition, Bora Biologics now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites in Rockville, Maryland and San Diego, California, along with a development facility in Zhubei, Taiwan. The expanded platform supports more than four active commercial programs, with over 120 completed GMP batches supplying markets including the US, EU, Japan, Canada, and the UK.
The deal comes amid evolving regulatory and supply chain dynamics, as biotech and pharmaceutical companies increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics' US network has undergone five FDA inspections, including two at the Rockville site and one PMDA review in 2025, all with clean results. The combined platform has supported more than 33 biologics and 15 biosimilars, offering reduced offshore dependency and domestically anchored infrastructure.
"This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply," said Bobby Sheng, Chairman and CEO of Bora Group. "As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities."
Bora Group intends to integrate its US drug substance capabilities with its existing sterile drug product capabilities over the next 12 to 18 months, aiming to provide a seamless, fully integrated development-through-commercial biologics solution. This vertical integration could reduce lead times and manufacturing risks for clients, potentially accelerating time-to-market for new biologics and biosimilars.
The implications for the pharmaceutical industry are significant. By expanding its US footprint, Bora Biologics positions itself as a key player in the biologics CDMO market, offering capacity that can help address supply chain vulnerabilities exposed by recent global disruptions. For biotech companies, a reliable US-based manufacturing partner means less reliance on overseas facilities, which can face geopolitical and logistical hurdles. Patients ultimately benefit from a more stable supply of critical biologic medicines.
For more information, visit Bora Pharmaceuticals or Bora CDMO.
